Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy

Translational Research

Volumn 161, Issue 4, 2013, Pages 265-283

  Hackett, Perry B ^a   Largaespada, David A ^a   Switzer, Kirsten C ^b   Cooper, Laurence J N ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; DNA DIRECTED RNA POLYMERASE III; K RAS PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; METHYL CPG BINDING PROTEIN 2; POLYADENYLATED RNA; PROTEIN P53; RNA POLYMERASE II; SPACER DNA; TRANSPOSASE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN RECOGNITION; CANCER SUSCEPTIBILITY; CELLS; DNA SEQUENCE; DNA SUPERCOILING; DNA TRANSPOSITION; EX VIVO GENE TRANSFER; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENETIC RISK; GENETIC TRANSFORMATION; GENETIC VARIABILITY; GENOME; HUMAN; HUMAN CELL; HUMAN GENOME; MUTATION RATE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN BINDING; PROTO ONCOGENE; RETROPOSON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE RECEPTOR GENE; TRANSCRIPTION INITIATION; TRANSPOSON; TUMOR SUPPRESSOR GENE; VIRUS DNA CELL DNA INTERACTION; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

EID: 84875138464     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.12.005     Document Type: Review

References (207)

1. E.F. Wagner, L. Covarrubias, T.A. Stewart, and B. Mintz Prenatal lethalities in mice homozygous for human growth hormone gene sequences integrated in the germ line Cell 35 1983 647 655
2. S. Hacein-Bey-Abina, F. LaDeist, and F. Carlier Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy N Engl J Med 346 2002 1185 1193
3. S. Hacein-Bey-Abina, C. von Kalle, and M. Schmidt A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency N Engl J Med 348 2003 255 256
4. S. Hacein-Bey-Abina, J. Hauer, and A. Lim Efficacy of gene therapy for X-linked severe combined immunodeficiency N Engl J Med 363 2010 355 364
5. S. Hacein-Bey-Abina, C. von Kalle, and M. Schmidt LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 Science 302 2003 415 419
6. M.P. McCormack, A. Forster, L. Drynan, R. Pannell, and T.H. Rabbitts The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development Mol Cell Biol 23 2003 9003 9013
7. U.P. Dave', N.A. Jenkins, and N.G. Copeland Gene therapy insertional mutagenesis insights Science 303 2004 33
8. M.P. McCormack, and T.H. Rabbitts Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency N Engl J Med 350 2004 913 922
9. C.H. Nam, and T.H. Rabbitts The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion Mol Ther 13 2006 15 25
10. N.B. Woods, V. Bottero, M. Schmidt, C. von Kalle, and I.M. Verma Gene therapy: therapeutic gene causing lymphoma Nature 440 2006 1123
11. H.B. Gaspar, S. Cooray, and K.C. Gilmour Long-term persistence of a polyclonal T cell repertoire after gene therapy fo rX-linked severe combined immunodeficiency Sci Transl Med 3 2011 97ra79
12. M.G. Ott, M. Schmidt, and K. Schwarzwaelder Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 Nat Med 5 2006 401 409
13. E.M. Kang, U. Choi, and N. Theobald Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils Blood 115 2010 783 791
14. S. Stein, M.G. Ott, and S. Schultze-Strasser Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease Nat Med 16 2010 198 204
15. C. Baum, J. Dullmann, and Z. Li Side effects of retroviral gene transfer into hematopoietic stem cells Blood 101 2003 2099 2114
16. C. Baum, and B. Fehse Mutagenesis by retroviral transgene insertion: risk assessment and potential alternatives Curr Opin Mol Ther 5 2003 458 462
17. C. Baum, C. von Kalle, and F.J. Staal Chance or necessity? Insertional mutagenesis in gene therapy and its consequences Mol Ther 9 2004 5 13
18. O. Kustikova, B. Fehse, and U. Modlich Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking Science 308 2005 1171 1174
19. L. Muul, L.M. Tuschong, and S.L. Soenen Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial Blood 101 2003 2563 2569
20. M. Schmidt, D.A. Carbonaro, and C. Speckmann Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates Nat Med 9 2003 463 468
21. A. Aiuti, F. Ficara, F. Cattaneo, C. Bordignon, and M.G. Roncarolo Gene therapy for adenosine deaminase deficiency Curr Opin Allergy Clin Immunol 3 2004 461 466
22. H.B. Gaspar, E. Bjorkegren, and K. Parsley Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning Mol Ther 14 2006 505 513
23. A. Aiuti, B. Cassani, and G. Andolfi Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy J Clin Invest 117 2007 2233 2240
24. B. Cassani, E. Montini, and G. Maruggi Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy Blood 114 2009 3546 3556
25. K. Boztug, M. Schmidt, and A. Schwarzer Stem-cell gene therapy for the Wiskott-Aldrich Syndrome N Engl J Med 363 2010 1918 1927
26. S. Buonamici, S. Chakraborty, V. Senyuk, and G. Nucifora The role of EVI1 in normal and leukemic cells Blood Cells Mol Dis 31 2003 206 212
27. S. Buonamici, D. Li, and Y. Chi EVI1 induces myelodysplastic syndrome in mice J Clin Invest 114 2004 713 719
28. Z. Li, J. Dullmann, and B. Schiendlmeier Murine leukemia induced by retroviral gene marking Science 296 2002 497
29. L. Biasco, C. Baricordi, and A. Aiuti Retroviral integrations in gene therapy trials Mol Ther 20 2012 709 716
30. R. Gabriel, M. Schmidt, and C. von Kalle Integration of retroviral vectors Curr Opin Immunol 24 2012 592 597
31. J. Scholler, T.L. Brady, and G. Binder-Scholl Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells Sci Transl Med 4 2012 132 153
32. J.C. van der Loo, W.P. Swaney, and A. Terwilliger Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency Gene Ther 19 2012 872 876
33. C.H. June, B.R. Blazar, and J.L. Riley Engineering lymphocyte subsets: tools, trials and tribulations Nat Rev Immunol 9 2006 704 716
34. K. Schwarzwaelder, S.J. Howe, and M. Schmidt Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo J Clin Invest 117 2007 2241 2249
35. S. Newrzela, K. Cornils, and Z. Li Resistance of mature T cells to oncogene transformation Blood 112 2008 2278 2286
36. C. Cattoglio, G. Maruggi, and C. Bartholomae High-definition mapping of retroviral integration sites defines the fate of allogeneic T cells after donor lymphocyte infusion PLoS One 5 2010 e15688
37. G.P. Wang, C.C. Berry, and N. Malani Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial Blood 115 2010 4356 4366
38. A. Deichmann, M.H. Brugman, and C.C. Bartholomae Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy Mol Ther 19 2011 2031 2039
39. E. Montini, D. Cesana, and M. Schmidt The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy J Clin Invest 119 2009 964 975
40. O. Kustikova, M. Brugman, and C. Baum The genomic risk of somatic gene therapy Semin Cancer Biol 20 2010 269 278
41. E. Almarza, F. Zhang, and G. Santilli Correction of SCID-X1 using an enhancerless Vav promoter Hum Gene Ther 22 2011 263 270
42. C. Baum Parachuting in the epigenome: the biology of gene vector insertion profiles in the context of clinical trials EMBO Mol Med 3 2011 75 77
43. C. Wu, and C.E. Dunbar Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity Front Med 5 2011 356 371
44. G.D. Trobridge Genotoxicity of retroviral hematopoietic stem cell gene therapy Expert Opin Biol Ther 11 2011 581 593
45. M.W. Huston, M.H. Brugman, S. Horsman, A.P. Stubbs, P.J. van der Spek, and G. Wagemaker Comprehensive investigation of the parameters of viral integration site analysis and their effects on the gene annotations produced Hum Gene Ther 23 2012 1209 1219
46. J. Corrigan-Curay, O. Cohen-Haguenauer, and M. O'Reilly Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy Mol Ther 20 2012 1084 1094
47. A. Aiuti, R. Bacchetta, R. Seger, A. Villa, and M. Cavazzana-Calvo Gene therapy for primary immunodeficiencies: part 2 Curr Opin Immunol 24 2012 1 7
48. L. Scobie A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity Mol Ther 17 2009 1031 1038
49. A. Deichmann, S. Hacein-Bey-Abina, and M. Schmidt Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy J Clin Invest 117 2007 2225 2232
50. R. Gabriel, R. Eckenberg, and A. Paruzynski Comprehensive genomic access to vector integration in clinical gene therapy Nat Med 15 2009 1431 1436
51. A.F. Kolb, C.J. Coates, J.M. Kaminski, J.B. Summers, A.D. Miller, and D.J. Segal Site-directed genome modification: nucleic acid and protein modules for targeted integration and gene correction Trends Biotech 23 2005 399 406
52. J. de Jong, J. deRidder, and Weyden L. van der Computational identification of insertional mutagenesis targets for cancer gene discovery Nucl Acids Res 39 2011 e105
53. H.N. March, A.G. Rust, and N.A. Wright Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis Nat Genet 43 2011 1202 1209
54. A.J. Dupuy Transposon-based screens for cancer gene discovery in mouse models Semin Cancer Biol 20 2010 261 268
55. T.L. Bergemann, T.K. Starr, and H. Yu New methods for finding common insertion sites and co-occurring common insertion sites in transposon- and virus-based genetic screens Nucl Acids Res 40 2012 3822 3833
56. V.M. Howell Sleeping Beauty-a mouse model for all cancers? Cancer Lett 317 2012 1 8
57. K.M. Mann, J.M. Ward, C.C. Yew Australian Pancreatic Cancer Genome Initiative Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma Proc Natl Acad Sci USA 109 2012 5934 5941
58. L. van der Weyden, A. Papaspyropoulos, and G. Poulogiannis Loss of rassf1a synergizes with deregulated runx2 signaling in tumorigenesis Cancer Res 72 2012 3817 3827
59. R.J. Bergerson, L.S. Collier, and A.L. Sarver An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model Blood 119 2012 4512 4523
60. L. van der Weyden, M.J. Arends, and A.G. Rust Increased tumorigenesis associated with loss of the tumor suppressor gene Cadm Mol Cancer 11 2011 29
61. R.N. Oliveira-Cobucci, H. Saconato, and P.H. Lima Comparative incidence of cancer in HIV-AIDS patients and transplant recipients Cancer Epidemiol 36 2012 e69 e73
62. G.P. Wang, B.L. Levine, and G.K. Binder Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells Mol Ther 17 2009 844 850
63. D. Cesana, J. Squaldino, and L. Rudilosso Whole transcriptome characterization of aberrant splicing events induced by lentivirus vector integrations J Clin Invest 122 2012 1667 1676
64. T. Brady, and F.D. Bushman Nondividing cells: a safer bet for integrating vectors? Mol Ther 19 2011 640 641
65. C. Cattoglio, G. Facchini, and D. Sartori Hot spots of retroviral integration in human CD34+ hematopoietic cells Blood 110 2007 1770 1778
66. A. Nowrouzi, H. Glimm, C. von Kalle, and M. Schmidt Retroviral vectors: post entry events and genomic alterations Viruses 3 2011 429 455
67. A. Biffi, C.C. Bartolomae, and D. Cesana Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection Blood 117 2012 5332 5339
68. S.L. Roth, N. Malani, and F.D. Bushman Gammaretroviral integration into nucleosomal target DNA in vivo J Virol 85 2011 7393 7401
69. P.B. Hackett Integrating DNA vectors for gene therapy Mol Ther 15 2007 10 12
70. Y. Zhang, A. Satterlee, and L. Huang In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther 20 2012 1298 1304
71. P.B. Hackett, D.A. Largaespada, and L.J.N. Cooper A transposon and transposase system for human application Mol Ther 18 2010 674 683
72. C.S. Hackett, A.M. Geurts, and P.B. Hackett Predicting preferential DNA vector insertion sites: implications for functional genomics and gene therapy Genome Biol 8 Suppl 1 2007 S12
73. 1000 Genomes Project Consortium, G.R. Abecasis, and D. Altshuler A map of human genome variation from population-scale sequencing Nature 467 2010 1061 1073
74. ENCODE Project An integrated encyclopedia of DNA elements in the human genome Nature 489 2012 57 74
75. E.S. Lander, L.M. Linton, and B. Birren Initial sequencing and analysis of the human genome Nature 409 2001 860 921
76. J.C. Venter, M.D. Adams, and E.W. Myers The sequence of the human genome Science 291 2001 1304 1351
77. R. Cordaux The human genome in the LINE of fire Proc Natl Acad Sci USA 105 2008 19033 19034
78. A.P. de Koning, W. Gu, T.A. Castoe, M.A. Batzer, and D.D. Pollock Repetitive elements may comprise over two-thirds of the human genome PLoS Genet 7 2011 e1002384
79. C.R. Beck, P. Collier, and C. Macfarlane LINE-1 retrotransposition activity in human genomes Cell 141 2010 1159 1170
80. T. Brady, Y.N. Lee, and K. Ronen Integration target site selection by a resurrected human endogenous retrovirus Genes Dev 23 2009 633 642
81. B. Brouha, J. Schustak, and R.M. Badge Hot L1s account for the bulk of retrotransposition in the human population Proc Natl Acad Sci USA 100 2003 5280 5288
82. E. Lee, R. Iskow, and L. Yang Landscape of somatic retrotransposition in human cancers Science 337 2012 967 971
83. S. Solyom, A.D. Ewing, and E.P. Rahrmann Extensive somatic L1 retrotransposition in colorectal tumors Genome Res 22 2012 2328 2338
84. B.A. Dombroski, S.L. Mathias, E. Nanthakumar, A.F. Scott, and H.H. Kazazian Jr. Isolation of an active human transposable element Science 254 1991 1805 1808
85. J.V. Moran, S.E. Holmes, T.P. Naas, R.J. DeBerardinis, J.D. Boeke, and H.H. Kazazian Jr. High frequency retrotransposition in cultured mammalian cells Cell 87 1996 917 927
86. H.H. Kazazian, and J.L. Goodier LINE drive: retrotransposition and genome instability Cell 110 2002 277 280
87. P.L. Deininger, J.V. Moran, M.A. Batzer, and H.H. Kazazian Jr. Mobile elements and mammalian genome evolution Curr Opin Genet Dev 13 2003 651 658
88. H.H. Kazazian Mobile elements: drivers of genome evolution Science 303 2004 1626 1632
89. R. Cordaux, and M.A. Batzer The impact of retrotransposons on human genome structure Nat Rev Genet 10 2009 691 703
90. A.D. Ewing, and H.H. Kazazian Jr. Whole-genome resequencing allows detection of many rare LINE-1 insertion alleles in humans Genome Res 21 2011 985 990
91. K.H. Burns, and J.D. Boeke Human transposon tectonics Cell 149 2012 740 752
92. N.G. Coufal, J.L. Garcia-Perez, and G.E. Peng L1 retrotransposition in human neural progenitor cells Nature 460 2009 1127 1131
93. J.K. Baillie, M.W. Barnett, and K.R. Upton Somatic retrotransposition alters the genetic landscape of the human brain Nature 479 2011 534 537
94. A.R. Muotri, M.C. Marchetto, and N.G. Coufal L1 retrotransposition in neurons is modulated by MeCP2 Nature 443 2010 443 446
95. C.R. Huang, A.M. Schneider, and Y. Lu Mobile interspersed repeats are major structural variants in the human genome Cell 141 2010 1171 1182
96. R.C. Iskow, M.T. McCabe, and R.E. Mills Natural mutagenesis of human genomes by endogenous retrotransposons Cell 141 2010 1253 1261
97. J.L. Garcia-Perez, M. Morell, and J.O. Scheys Epigenetic silencing of engineered L1 retrotransposition events in human embryonic carcinoma cells Nature 466 2010 769 773
98. W. Doerfler Impact of foreign DNA integration on tumor biology and on evolution via epigenetic alterations Epigenomics 4 2012 41 49
99. J. Bao, and W. Yan Male germline control of transposable elements Biol Reprod 86 2012 162
100. B.J. Wagstaff, D.J. Hedges, and R.S. Derbes Rescuing Alu: recovery of new inserts shows LINE-1 preserves Alu activity through A-tail expansion PLoS Genet 8 2012 e1002842
101. Y. Zhang, I.A. Maksakova, L. Gagnier, L.N. van de Lagemaat, and D.L. Mager Genome-wide assessments reveal extremely high levels of polymorphism of two active families of mouse endogenous retroviral elements PLoS Genet 4 2008 e1000007
102. G. Liu, E.L. Aronovich, Z. Cui, C.B. Whitley, and P.B. Hackett Excision of Sleeping Beauty transposons: parameters and applications to gene therapy J Gene Med 6 2004 574 583
103. R.H. Plasterk, Z. Izsvák, and Z. Ivics Resident aliens: the Tc1/mariner superfamily of transposable elements Trends Genet 15 1999 326 332
104. Z. Ivics, P.B. Hackett, R.H. Plasterk, and Z. Izsvak Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells Cell 91 1997 501 510
105. S.R. Yant, L. Meuse, W. Chiu, Z. Ivics, Z. Izsvak, and M.A. Kay Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system Nat Genet 25 2000 35 41
106. A.M. Geurts, Y. Yang, and K.J. Clark Gene transfer into genomes of human cells by the Sleeping Beauty transposon system Mol Ther 8 2003 108 117
107. H. Zayed, Z. Izsvak, O. Walisko, and Z. Ivics Development of hyperactive Sleeping Beauty transposon vectors by mutational analysis Mol Ther 9 2004 292 304
108. S.R. Yant, J. Park, Y. Huang, J.G. Mikkelsen, and M.A. Kay Mutational analysis of the N-terminal DNA-binding domain of Sleeping Beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells Mol Cell Biol 24 2004 9239 9247
109. L. Mátés, M.K. Chuah, and E. Belay Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates Nat Genet 41 2009 753 761
110. Z. Ivics, C.D. Kaufman, H. Zayed, C. Miskey, O. Walisko, and Z. Izsvak The Sleeping Beauty transposable element: evolution, regulation and genetic applications Curr Issues Mol Biol 6 2004 43 55
111. S.R. Yant, X. Wu, and Y. Huang Nonrandom insertion site preferences for the SB transposon in vitro and in vivo Mol Ther 9 2004 S309
112. G. Liu, K. Yae, and A.R. Srinivassan Target-site preference for Sleeping Beauty transposons J Mol Biol 346 2005 161 173
113. A.M. Geurts, C.S. Hackett, and J.B. Bell DNA structural patterns influence integration site preferences for mobile elements Nucl Acids Res 34 2006 2803 2811
114. C. Berry, S. Hannenhalli, J. Leipzig, and F.D. Bushman Selection of target sites for mobile DNA integration in the human genome PLoS Comp Biol 2 2006 e157
115. J.R. Ohlfest, J.L. Frandsen, and S. Fritz Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system Blood 105 2005 2691 2698
116. L. Liu, C. Mah, and B.S. Fletcher Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice Mol Ther 13 2006 1006 1015
117. E.L. Aronovich, R.S. McIvor, and P.B. Hackett The Sleeping Beauty transposon system: a non-viral vector for gene therapy Hum Mol Genet 20 R1 2011 14 20
118. J.B. Bell, E.L. Aronovich, J.M. Schreifels, T.C. Beadnell, and P.B. Hackett Duration of expression of Sleeping Beauty transposase in mouse liver following hydrodynamic DNA delivery Mol Ther 18 2010 1792 1802
119. A.A. Aravin, G.J. Hannon, and J. Brennecke The Piwi-piRNA pathway provides an adaptive defense in the transposon arms race Science 318 2007 761 764
120. N.V. Fedoroff Transposable elements, epigenetics, and genome evolution Science 338 2012 758 767
121. I.V. Nesmelova, and P.B. Hackett DDE Transposases: structural similarity and diversity Adv Drug Del Rev 62 2010 1187 1195
122. S.P. Montaño, Y.Z. Pigli, and P.A. Rice The Mu transpososome structure sheds light on DDE recombinase evolution Nature 491 2012 413 417
123. A.C. Wilber, J.L. Frandsen, A.M. Geurts, D.A. Largaespada, P.B. Hackett, and R.S. McIvor RNA as a source of transposase for Sleeping Beauty-mediated gene insertion and expression in somatic cells and tissues Mol Ther 13 2006 625 630
124. J. Urschitz, M. Kawasumi, and J. Owens Helper-independent piggyBac plasmids for gene delivery approaches: strategies for avoiding potential genotoxic effects Proc Natl Acad Sci USA 107 2010 8117 8122
125. N.D. Hastie, and J.O. Bishop The expression of three abundance classes of messenger RNA in mouse tissues Cell 9 1976 761 774
126. A.M. Rushforth, and P. Anderson Splicing removes the Caenorhabditis elegans transposon Tc1 from most mutant pre-mRNAs Mol Cell Biol 16 1996 422 429
127. A. Hodgkinson, Y. Chen, and A. Eyre-Walker The large-scale distribution of somatic mutations in cancer genomes Hum Mutat 33 2012 136 143
128. B. Schuster-Böckler, and B. Lehner Chromatin organization is a major influence on regional mutation rates in human cancer cells Nature 488 2012 504 507
129. S. Djebali, C.A. Davis, and A. Merkel Landscape of transcription in human cells Nature 489 2012 101 108
130. C. Cheng, R. Alexander, and R. Min Understanding transcriptional regulation by integrative analysis of transcription factor binding data Genome Res 22 2012 1658 1667
131. A. Sanyal, B.R. Lajoie, G. Jain, and J. Dekker The long-range interaction landscape of gene promoters Nature 489 2012 109 113
132. R.E. Thurman, E. Rynes, and R. Humbert The accessible chromatin landscape of the human genome Nature 489 2012 75 82
133. J. Zhang, J. Markus, J. Bies, T. Paul, and L. Wolff Three murine leukemia virus integration regions within 100kb upstream of c-myb are proximal to the 5′ regulatory region of the gene through DNA looping J Virol 86 2012 10524 10532
134. A. Poleshko, I. Palagin, and R. Zhang Identification of cellular proteins that maintain retroviral epigenetic silencing: evidence for an antiviral response J Virol 82 2008 2313 2323
135. C. Alkan, B.P. Coe, and E.E. Eichler Genome structural variation discovery and genotyping Nat Rev Genet 12 2011 363 376
136. G.T. Marth, Z. Stoytcheva, and J. Urschitz The functional spectrum of low-frequency coding variation Genome Biol 12 2011 R84
137. K. Pelak, K.V. Shianna, and D. Ge The characterization of twenty sequenced human genomes PLoS Genet 6 2010 e1001111
138. D.G. MacArthur, S. Balasubramanian, and A. Frankish A systematic survey of loss-of-function variants in human protein-coding genes Science 335 2012 823 828
139. T. Wada, and F. Candotti Somatic mosaicism in primary immune deficiencies Curr Opin Allergy Clin Immunol 8 2008 510 514
140. A. Abyzov, A.E. Urban, M. Snyder, and M. Gerstein CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing Genome Res 21 2011 974 984
141. M. O'Huallachain, K.J. Karczewski, S.M. Weissman, A.E. Urban, and M.P. Snyder Extensive genetic variation in somatic human tissues Proc Natl Acad Sci USA 109 2012 18018 18023
142. J.M. Kidd, T. Graves, and T.L. Newman A human genome structural variation sequencing resource reveals insights into mutational mechanisms Cell 143 2010 837 847
143. A.P. Boyle, E.L. Hong, and M. Hariharan Annotation of functional variation in personal genomes using RegulomeDB Genome Res 22 2012 1790 1797
144. D. Eide, and P. Anderson Insertion and excision of Caenorhabditis elegans transposable element Tc1 Mol Cell Biol 8 1998 737 746
145. J. Ellis Silencing and variegation of gammaretrovirus and lentivirus vectors Hum Gene Ther 16 2005 1241 1246
146. J.P. Blumenstiel Evolutionary dynamics of transposable elements in a small RNA world Trends Genet 27 2011 23 31
147. M.C. Siomi, K. Sato, D. Pezic, and A.A. Aravin PIWI-interacting small RNAs: the vanguard of genome defense Nat Rev Mol Cell Biol 12 2011 246 258
148. B.S. Garrison, S.R. Yant, J.G. Mikkelsen, and M.A. Kay Post-integrative gene silencing within the Sleeping Beauty transposition system Mol Cell Biol 27 2007 8824 8833
149. C. Rauschhuber, and A. Ehrhardt RNA interference is responsible for reduction of transgene expression after Sleeping Beauty transposase mediated somatic integration PLoS One 7 2012 e35389
150. T.W. Chalberg, J.L. Portlock, and E.C. Olivares Integration specificity of phage phiC31 integrase in the human genome J Mol Biol 357 2006 28 48
151. A. Ehrhardt, J.A. Engler, H. Xu, and M.A. Kay Molecular analysis of chromosomal rearrangements in mammalian cells after phiC31-mediated integration Hum Gene Ther 17 2006 1077 1094
152. D.A. Largaespada Transposon mutagenesis in mice Methods Mol Biol 530 2009 379 390
153. N.G. Copeland, and N.A. Jenkins Harnessing transposons for cancer gene discovery Nat Rev Genet 10 2010 696 706
154. H. Mikkers, and A. Berns Retroviral insertional mutagenesis: tagging cancer pathways Adv Cancer Res 88 2003 53 99
155. J. Jonkers, and A. Berns Retroviral insertional mutagenesis as a strategy to identify cancer genes Biochim Biophys Acta 1287 1996 29 57
156. M. van Lohuizen, and A. Berns Tumorigenesis by slow transforming retroviruses-an update Biochim Biophys Acta 1032 1990 213 235
157. D.A. Largaespada Genetic heterogeneity in acute myeloid leukemia: maximizing information flow from MuLV mutagenesis studies Leukemia 14 2000 1174 1184
158. M. Lu, N. Zhang, M. Maruyama, R.G. Hawley, and A.D. Ho Retrovirus-mediated gene expression in hematopoietic cells correlates inversely with growth factor stimulation Hum Gene Ther 7 1996 2263 2271
159. R.G. Hawley, F.H. Lieu, A.Z. Fong, and T.S. Hawley Versatile retroviral vectors for potential use in gene therapy Gene Ther 1 1994 136 138
160. S.R. Cherry, D. Biniszkiewicz, L. van Parijs, D. Baltimore, and R. Jaenisch Retroviral expression in embryonic stem cells and hematopoietic stem cells Mol Cell Biol 20 2000 7419 7426
161. G.S. Vassiliou, J.L. Cooper, and R. Rad Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice Nat Genetics 43 2011 470 475
162. A.J. Dupuy, L.M. Rogers, and J. Kim A modified Sleeping Beauty transposon system that can be used to model a wide variety of human cancers in mice Cancer Res 69 2009 8150 8156
163. L.S. Collier, C.M. Carlson, S. Ravimohan, A.J. Dupuy, and D.A. Largaespada Cancer gene discovery in solid tumors using transposon-based somatic mutagenesis in the mouse Nature 436 2005 272 276
164. A.J. Dupuy, K. Akagi, D.A. Largaespada, N.G. Copeland, and N.A. Jenkins Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system Nature 436 2005 221 226
165. L.S. Collier, D.J. Adams, and C.S. Hackett Whole-body Sleeping Beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality Cancer Res 69 2009 8429 8437
166. T.K. Starr, R. Allaei, and K.A. Silverstein A transposon-based genetic screen in mice identifies genes altered in colorectal cancer Science 323 2009 1747 1750
167. T.K. Starr, P.M. Scott, and B.M. Marsh A Sleeping Beauty transposon-mediated screen identifies murine susceptibility genes for adenomatous polyposis coli (Apc)-dependent intestinal tumorigenesis Proc Natl Acad Sci USA 108 2011 5765 5770
168. V.W. Keng, A. Villanueva, and D.Y. Chiang A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma Nat Biotech 27 2009 264 274
169. P.A. Pérez-Mancera, A.G. Rust, L. van der Weyden Australian Pancreatic Cancer Genome Initiative The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma Nature 486 2012 266 270
170. B. Jena, J.B. Dotti, and L.J. Cooper Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor Blood 116 2010 1035 1044
171. R. Brentjens, R. Yeh, Y. Bernal, I. Riviere, and M. Sadelain Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a Phase I clinical trial Mol Ther 18 2010 666 668
172. R.J. Brentjens, I. Rivière, and J.H. Park Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias Blood 118 2011 4817 4828
173. M. Kalos, B.L. Levine, and D.L. Porter T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci Transl Med 3 2011 95ra73
174. J.N. Kochenderfer, M.E. Dudley, and S.A. Feldman B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells Blood 119 2012 2709 2720
175. D.L. Porter, B.L. Levine, M. Kalos, A. Bagg, and C.H. June Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med 365 2011 725 733
176. C. Bonini, M. Grez, and C. Traversari Safety of retroviral gene marking with a truncated NGF receptor Nat Med 9 2003 367 369
177. H. Singh Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system Cancer Res 68 2008 2961 2971
178. P.V. Manuri piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies Hum Gene Ther 21 2010 427 437
179. H. Singh, P.R. Manuri, and S. Olivares Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies Cancer Res 71 2011 3516 3527
180. C.H. Lamers, S. Sleijfer, and A.G. Vulto Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience J Clin Oncol 24 2006 e20 e22
181. R.A. Morgan, J.C. Yang, M. Kitano, M.E. Dudley, C.M. Laurencot, and S.A. Rosenberg Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol Ther 18 2010 843 851
182. E. Montini, D. Cesana, and M. Schmidt Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration Nat Biotech 24 2006 687 696
183. U. Modlich, O.S. Kustikova, and M. Schmidt Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis Blood 105 2005 4235 4246
184. M.C. Jensen, P. Clarke, and G. Tan Human T lymphocyte genetic modification with naked DNA Mol Ther 1 2000 49 55
185. L.J. Cooper, L. Ausubel, and M. Gutierrez T lymphocytes for autologous cellular therapy for lymphoma Cytotherapy 8 2006 105 117
186. D.C. Deniger, K. Switzer, and T. Mi Bispecific T-cells expressing polyclonal repertoire of endogenous gs T-cell receptors and inntroduced CD19-specific chimeric antigen receptor Mol Ther 2013 (in press)
187. S.N. Maiti, H. Huls, and H. Singh Sleeping Beauty system to redirect T-cell specificity for human applications J Immunol 36 2013 112 123
188. P. Kebriaei, H. Huls, and B. Jena Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies Hum Gene Ther 23 2012 444 450
189. M. Sadelain, E.P. Papapetrou, and F.D. Bushman Safe harbours for the integration of new DNA in the human genome Nat Rev Cancer 12 2011 51 58
190. E.P. Papapetrou, G. Lee, and N. Malani Genomic safe harbors permit high beta-globin transgene expression in thalassemia induced pluirpotent stem cells Nat Biotech 29 2011 73 78
191. M.H. Porteus, and D. Baltimore Chimeric nucleases stimulate gene targeting in human cells Science 300 2003 763
192. F.D. Urnov, J.C. Miller, and Y.L. Lee Highly efficient endogenous human gene correction using designed zinc-finger nucleases Nature 435 2005 646 651
193. F.D. Urnov, E.J. Rebar, M.C. Holmes, H.S. Zhang, and P.D. Gregory Genome editing with engineered zinc finger nucleases Nat Rev Genet 11 2010 636 646
194. A. Lombardo, P. Genovese, and C.M. Beausejour Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery Nat Biotech 25 2007 1298 1306
195. E.E. Perez, J. Wang, and J.C. Miller Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases Nat Biotech 26 2008 808 816
196. N. Holt, J. Wang, and K. Kim Human hematopoietic stem progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo Nat Biotech 28 2012 839 847
197. Z. Ivics, A. Katzer, E.E. Stuwe, D. Fiedler, S. Knespel, and Z. Izsvak Targeted Sleeping Beauty transposition in human cells Mol Ther 15 2007 1137 1144
198. S.R. Yant, Y. Huang, B. Akache, and M.A. Kay Site-directed transposon integration in human cells Nucl Acids Res 35 2007 e50
199. K. Voigt, A. Gogol-Doring, and C. Miskey Retargeting Sleeping Beauty transposon insertions by engineered zinc finger DNA-binding domains Mol Ther 20 2012 1852 1862
200. I. Ammar, A. Gogol-Döring, and C. Miskey Retargeting transposon insertions by the adeno-associated virus Rep protein Nucl Acids Res 40 2012 6693 6712
201. Z. Wang, L. Lisowski, M.J. Finegold, H. Nakai, M.A. Kay, and M. Grompe AAV vectors containing rDNA homology display increased chromosomal integration and transgene persistence Mol Ther 20 2012 1902 1911
202. L. Lisowski, A. Lau, and Z. Wang Ribosomal DNA integrating rAAV-rDNA vectors allow for stable transgene expression Mol Ther 20 2012 1912 1923
203. A.J. Bogdanove, and D.F. Voytas TAL efffectors: customizable proteins for DNA targeting Science 333 2011 1843 1844
204. D.F. Carlson, S.C. Fahrenkrug, and P.B. Hackett Targeting DNA with fingers and TALENs Mol Ther Nuc Acids 1 2012 e3
205. H. Torikai, A. Reik, and P.Q. Liu A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR Blood 119 2012 5697 5705
206. Y. Nakazawa, L.E. Huye, and G. Dotti Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes J Immunother 32 2009 826 836
207. H. Li, V. Haurigot, and Y. Doyon In vivo genome editing restores hemostasis in a mouse model of hemophilia Nature 475 2011 217 221